The Conversation (0)
Akers Biosciences is marketing its rapid test for heparin-induced thrombocytopenia to hospitals in Puerto Rico.
Akers Biosciences (NASDAQ:AKER) is marketing its rapid test for heparin-induced thrombocytopenia to hospitals in Puerto Rico.
As quoted in the press release:
The Company believes Puerto Rico represents a large new market opportunity which is closely aligned to the U.S. and has more than 60 potential hospital targets.
Akers Bio has appointed a specialist independent outsourced sales group to represent the test in Puerto Rico as well as a leading channel partner with established logistical access in the region.
Akers Bio’s flagship PIFA Heparin/PF4 Rapid Assay and PIFA PLUSS PF4 tests were designed to quickly determine at — or near — the point-of-care if a patient being treated with the widely used blood thinner heparin may be developing HIT. This clinical syndrome reverses heparin’s intended therapeutic effect and transforms it into a clotting agent. Patients suffering HIT are at risk of developing limb- and life-threatening complications, so the timely test result provided by the Company’s Heparin/PF4 devices is paramount to effective and cost-efficient clinical decision making.
John J. Gormally, Chief Executive Officer of Akers Bio, commented: “Puerto Rico is a strategically important market for Akers Bio to target as an extension of our U.S. sales strategy. There are some 64 potential hospital customers on the island and we believe the opportunity to enable those prospective customers to generate significant cost savings through the timely diagnosis of HIT will be very attractive.”
About Akers Biosciences, Inc.
Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company’s state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.